Vericel Corporation (VCEL)

USD 56.25

(-0.78%)

Market Cap (In USD)

2.77 Billion

Revenue (In USD)

197.51 Million

Net Income (In USD)

-3.18 Million

Avg. Volume

339.86 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
32.31-61.49
PE
-
EPS
-
Beta Value
1.667
ISIN
US92346J1088
CUSIP
92346J108
CIK
887359
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Dominick C. Colangelo Esq.
Employee Count
-
Website
https://vcel.com
Ipo Date
1997-02-04
Details
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.